MIST News & Events

Milestone Pharmaceuticals announced the appointment of David Sandoval as General Counsel and Chief Compliance Officer, CCO. Sandoval will serve as a member of Milestone's executive leadership team and will provide business-focused legal counsel across all functional areas.

Milestone Pharmaceuticals granted equity awards, in the form of a total of 419,000 options to purchase the Company's common shares, pursuant to the Company's 2021 Inducement Plan, previously approved by the Company's Compensation Committee and the Board of Directors, as a material inducement to the hiring of two new employees. The Options have a grant date of February 2, 2026, and an exercise price of $1.96 per share, which is equal to the closing price of Milestone's common shares on the grant date. The shares subject to the Options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter. The Option awards are subject to the award holder's continuous service through each vesting date and to the terms and conditions of the Plan and its standard forms of grant agreements thereunder.

Milestone Pharmaceuticals announced that cardamyst nasal spray, its first commercial product, is now available through U.S. retail pharmacies. Cardamyst is a prescription medication indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia to sinus rhythm in adults. Implementation of a rapid commercialization plan is underway with a national sales force to be deployed in mid-February 2026.

Milestone Pharmaceuticals announced the acceptance of a Marketing Authorization Application, MAA, by the European Medicines Agency, EMA, seeking the approval of etripamil nasal spray, developed to be the first rapid, reliable option in the treatment of paroxysmal supraventricular tachycardia, PSVT, outside of the healthcare setting. Etripamil, which has the conditionally approved brand name TACHYMIST in Europe, is an investigational, novel calcium channel blocker delivered via a nasal spray by the patient for the potential treatment of PSVT and other cardiac arrhythmias. A decision on approval is expected by the first quarter of 2027.